[ Price : $8.95]
A Washington Post opinion article takes issue with FDAs recent decision to reject a low-dose atropine treatment for pediatric myop...[ Price : $8.95]
FDA moves to blunt criticism of the Commissioners National Priority Voucher Program with a news release containing 18 questions an...[ Price : $8.95]
FDA warns Mark Dacey of Denver, CO, about failing to obtain informed consent for two clinical investigations he conducted.[ Price : $8.95]
FDA and industry representatives report agreement on several issues in the 1/21 MDUFA 6 negotiating session.[ Price : $8.95]
FDA approves changes to the isotretinoin REMS to take effect in 180 days.[ Price : $8.95]
FDA issues a Warning Letter to Bio-Medical Pharmaceutical Manufacturing Corporation, citing widespread GMP violations at the compa...[ Price : $8.95]
FDA accepts for priority review a Takeda NDA for TAK-861 (oveporexton) as a potential first-in-class treatment for narcolepsy Type...[ Price : $8.95]
FDA issues Moderna a refusal-to-file letter on its BLA for an investigational seasonal influenza vaccine mRNA-1010, despite the co...